Bottom line
XLV vs GGHCX: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and GGHCX (INVESCO Health Care Fund) share a meaningful slice of their top holdings — about 55% by weight.
XLV is cheaper at 0.08% vs 1.07% — a difference of $99 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +2.6% for GGHCX.
GGHCX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
XLV vs GGHCX side by side
| XLV | GGHCX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | Invesco |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 1.07% |
| Annual cost per $10k | $8 | $107 |
| 10-yr cost on $10k (prospectus) | $103 | $1,784 |
| Max front load | None | 5.5% |
| 12b-1 fee | 0.02% | 0.25% |
| 1-yr return | +14.5% | +9.2% |
| 5-yr return (annualized) | +8.1% | +2.6% |
| 10-yr return (annualized) | +9.8% | +5.8% |
| Best quarter | +14.5% | +19.6% |
| Worst quarter | −12.7% | −16.5% |
| Net assets (fund) | $40.6B | $1.2B |
| Number of holdings | 65 | 82 |
| Portfolio turnover | 2% | 59% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | GGHCX | Difference |
|---|---|---|---|
| 2025 | +14.5% | +15.5% | −1.0% |
| 2024 | +2.5% | +4.0% | −1.5% |
| 2023 | +2.0% | +3.1% | −1.1% |
| 2022 | −2.1% | −13.5% | +11.5% |
| 2021 | +25.9% | +12.2% | +13.7% |
| 2020 | +13.3% | +14.5% | −1.2% |
| 2019 | +20.7% | +32.0% | −11.3% |
| 2018 | +6.3% | +0.5% | +5.8% |
| 2017 | +21.7% | +15.5% | +6.2% |
| 2016 | −2.8% | −11.7% | +8.9% |
Source: Fund prospectus bar charts
Holdings overlap
10 of XLV's top 25 holdings also appear in GGHCX's top 25.
| Holding | XLV | GGHCX |
|---|---|---|
| Eli Lilly & Co | 16.51% | 10.59% |
| Johnson & Johnson | 10.64% | 6.76% |
| AbbVie Inc | 7.74% | 4.03% |
| UnitedHealth Group Inc | 6.57% | 6.17% |
| Merck & Co Inc | 5.52% | 4.59% |
| Thermo Fisher Scientific Inc | 3.24% | 1.55% |
| Gilead Sciences Inc | 2.73% | 3.63% |
| CVS Health Corp | 2.30% | 2.52% |
| Vertex Pharmaceuticals Inc | 2.19% | 2.01% |
| Cardinal Health Inc | 0.97% | 2.10% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
GGHCX top 10
- Eli Lilly and Co. — 10.59%
- Johnson & Johnson — 6.76%
- UnitedHealth Group Inc. — 6.17%
- Invesco Private Prime Fund — 4.67%
- Merck & Co., Inc. — 4.59%
- AbbVie Inc. — 4.03%
- Gilead Sciences, Inc. — 3.63%
- argenx SE — 3.24%
- CVS Health Corp. — 2.52%
- Welltower Inc. — 2.34%
FAQ
What is the difference between XLV and GGHCX?
Which is cheaper, XLV or GGHCX?
Should I own both XLV and GGHCX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.